Bruton's Tyrosine Kinase Inhibitors for Mature B-Cell Neoplasms: Focus on Efficacy and Safety of Available Agents

Bruton's Tyrosine Kinase Inhibitors for Mature B-Cell Neoplasms: Focus on Efficacy and Safety of Available Agents is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians.

Published Date: October 28, 2019
Expiration Date: October 28, 2020

Credits: 1.5 hour (0.15 ceu)

Goal:
The goal of this educational activity is to inform and educate oncology, managed care and specialty pharmacists on differences in pharmacology, efficacy, and safety of BTK inhibitors and roles that pharmacists can play to drive appropriate access to and use of BTK inhibitors to optimize outcomes for patients with mature B-cell neoplasms.

Educational Objectives:
Upon completion of this program, participants should be better able to:
• Compare and contrast the BTK inhibitors, including their pharmacological differences
• Discuss key published clinical trials, ongoing clinical trials, and guideline recommendations for BTK inhibitors in MCL and CLL
• Design a treatment plan involving an appropriate BTK inhibitor and corresponding safety considerations
• Formulate effective strategies for ensuring the proper selection and use of BTK inhibitors in the care of individual patients and patient populations

Additional details will be posted as soon as information is available.